Evidence map›Paper›PMID 38510286›Full record

ReviewJACC. CardioOncology2024

Cardiac Troponin in Patients With Light Chain and Transthyretin Cardiac Amyloidosis:

Laura De Michieli, Alberto Cipriani, Sabino Iliceto, Angela Dispenzieri, Allan S Jaffe

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JACC. CardioOncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 35 citations in OpenAlex.

  1. Role of Troponins in CardioOncology.Current treatment options in oncology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Laura De MichieliDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Alberto CiprianiDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Sabino IlicetoDepartment of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Allan S JaffeCardiovascular Department, Mayo Clinic and Medical School, Rochester, Minnesota, USA.
University of Padua · ITMayo Clinic · USWinnMed · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · MAYO CLINIC ARIZONA · 2025 to 2025
$2.2M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

Cardiac amyloidosis (CA) is an infiltrative disease caused by amyloid fibril deposition in the myocardium; the 2 forms that most frequently involve the heart are amyloid light chain (AL) and amyloid transthyretin (ATTR) amyloidosis. Cardiac troponin (cTn) is the biomarker of choice for the detection of myocardial injury and is frequently found to be elevated in patients with CA, particularly with high-sensitivity assays. Multiple mechanisms of myocardial injury in CA have been proposed, including cytotoxic effect of amyloid precursors, interstitial amyloid fibril infiltration, coronary microvascular dysfunction, amyloid- and non-amyloid-related coronary artery disease, diastolic dysfunction, and heart failure. Regardless of the mechanisms, cTn values have relevant prognostic (and potentially diagnostic) implications in both AL and ATTR amyloidosis. In this review, the authors discuss the significant aspects of cTn biology and measurement methods, potential mechanisms of myocardial injury in CA, and the clinical application of cTn in the management of both AL and ATTR amyloidosis.

Indexed as

amyloidosisdiagnosismyocardial injuryprognosistroponin

Identifiers

PMID38510286
PMCPMC10950441
OpenAlexW4391952996

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.